Despite heavy demand for its weight-loss and diabetes treatments, limited supply hobbled Eli Lilly's fourth-quarter sales.
Investor's Business Daily on MSN6d
Eli Lilly Jumps, Reversing Its Weight-Loss Setback, On A Strong 2025 OutlookEli Lilly stock reversed higher Thursday on its upbeat outlook despite lighter-than-expected fourth-quarter sales of its well-known weight-loss and diabetes drugs.Please watch the video at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback